" /> Internet and IP Law Roundup: March 2006 Archives

« February 2006 | Main | April 2006 »

March 31, 2006

Trademarks Are A Means To Extend Leverage Beyond Patent Expiration

Trademarks Are A Means To Extend Leverage Beyond Patent Expiration:


It may come as no surprise to some that a means to extend leverage for a product or brand beyond a patent term is the successful implementation of a comprehensive trademark portfolio. This is especially true in the pharmaceutical industry where a product life cycle could be exploited beyond the term of a patent by developing a portfolio of trademarks to boost and protect a brand image in the marketplace so that long after a patent expires, consumers continue to use the brand instead of switching to generic versions that may cost less.


Creation of a comprehensive trademark portfolio is no easy task. In essence the process is akin to developing a no-holds-barred media awareness program. That is why more and more pharmaceutical companies advertise their products on television and in the print media. Educating the public in addition to the doctors and pharmacists clearly adds an advantage as the images of products play into the minds of the consumers. In home-care medical devices are also heavily advertised.


In Brand New Challenge (see winter 2006 issue of IP Review), Pfizer is mentioned as a company doing just that. Pfizer has built an instantly recognizable brand for Viagra through key trademark registrations. Who doesn’t know about the little blue diamond shaped pill?


It seems that the trick is to trademark all of the distinctive elements of a product, such as the name, logo, shape and color of the product. At the very least, this will make it difficult for knock-off companies to produce products that have similar attributes.


Of course, there are some drawbacks. As more and more trademarks are filed, it will become increasingly difficult to secure federal protection for brands. Also, developing names for products, especially for pharmaceuticals, will become more difficult – the Food and Drug Administration has a stringent policy for accepting new product names.


An interesting question is whether a trademark protection policy could work for products in other technology industries? In fast-paced technology sectors, products may die off before the expiration of a patent, so it seems less necessary to invest in this type of brand development. However, for other technology areas where products have longer life cycles, it may seem fitting to invest in the development of a strong brand identity.


One key element to remember is that trademark protection can last well beyond the twenty year patent limit, so long as the trademark remains in use. It will be interesting to see how well trademarks continue to protect products long after their associated patents have expired.



March 22, 2006

CNN.com - 'Lion' daughters win landmark case - Mar 22, 2006

CNN.com - 'Lion' daughters win landmark case - Mar 22, 2006:


JOHANNESBURG, South Africa (AP) -- Three impoverished South African women, whose father wrote "The Lion Sleeps Tonight," have won a six-year battle for royalties in a landmark case that could affect musicians worldwide.

No one is saying how many millions will go to the daughters of the late composer Solomon Linda, who died in poverty from a curable kidney disease in 1962 at age 53.

But the family's settlement with New York-based Abilene Music, which gives Linda's heirs 25 percent of past and future royalties, has broad implications.

DesMoinesRegister.com

DesMoinesRegister.com:


Two Des Moines companies have found themselves in the middle of separate trademark disputes, with one also being accused of patent infringement by one of the nation's largest makers of health care products.

Johnson & Johnson and a subsidiary, McNeil-PPC Inc., sued Qualis Inc. last week in U.S. District Court in Des Moines. They alleged that Qualis has spent the past two years selling "warming liquid personal lubricants" to three major pharmacy chains in packages that look remarkably like those produced by McNeil's K-Y brand.

Johnson & Johnson also alleged that since February, Qualis has violated its patent on the composition and methods of use for the K-Y Warming Liquid. The plaintiffs said their product is used, among other things, to "enhance the intimacy of the sexual experience."

March 21, 2006

Google Sued Over Page Rank

Google Sued Over Page Rank:


Technology & Marketing Law Blog: Google Sued Over Rankings - KinderStart.com v. Google.



France OKs bill opening iTunes, iPod | MacMinute News

France OKs bill opening iTunes, iPod | MacMinute News:


French lawmakers approved an online copyright bill today that would require Apple to open the proprietary format behind its iTunes music store and iPod players, reports the Associated Press. "The draft law -- which also introduces new penalties for music pirates -- would force Apple Computer Inc., Sony Corp. and others to share proprietary copy-protection technologies so that rivals can offer compatible services and players," notes the story. French lawmakers approved the bill 296-193. The Senate must now debate and vote on the new legislation, which is expected to begin in May.

RED HERRING | Methods Patents Go to Court

RED HERRING | Methods Patents Go to Court:


In a case that could have broad implications in the biotech industry and elsewhere, the question of whether or not natural phenomena are patentable will come before the U.S. Supreme Court Tuesday.
 
Laboratory Corp. v. Metabolite Laboratories, a patent infringement case regarding diagnostic methods, was appealed to the high court to determine if laws of nature, natural phenomena, and abstract ideas are patentable.
 
While a decision could significantly impact the hotly contested topics of software and business method patents, the court would have to stray significantly from the case history to do so.
 
In fact, the U.S. solicitor general has recommended that the court not make a determination on whether or not the patent is valid, because that issue had not been developed in the lower courts.
 

Philadelphia Business Journal: European patent for CollaGenex rosacea drug - 2006-03-21

Philadelphia Business Journal: European patent for CollaGenex rosacea drug - 2006-03-21:


The European Patent Office on Tuesday issued a notice of allowance for CollaGenex Pharmaceuticals' patent application covering the use of sub-antimicrobial doxycycline in the treatment of acne and rosacea.

The Newtown, Pa., pharmaceutical company is seeking approval of its new drug candidate Oracea, which contains doxycycline, for the treatment of rosacea in Europe and the United States.

"This notice of allowance by the European Patent Office is another important milestone as we seek to maximize the value of Oracea ," said Colin W. Stewart, president and CEO of CollaGenex (NASDAQ:CGPI). "As we engage in discussions with potential European partners for rights to market Oracea in Europe, we are working to enhance the value of this asset by seeking intellectual property protections and pursuing regulatory marketing approval."

EETimes.com - Analysis: Winning the patent game in Asia

EETimes.com - Analysis: Winning the patent game in Asia:


We've heard so much about it over the last several years that intellectual property (IP) issues hardly get us excited. Yes, we all know about both sides of the story — the complaints by both patent holders mostly outside Asia and those in Asia new to the patent regime.
A recent report by the U.S.-based Manufacturing Policy Project concludes that companies from countries with weak IP protection are copying technologies from unprotected patent applications that the U.S. Patent and Trademark Office (USPTO) and Japan's Patent Office (JPO) post on the Internet. The JPO found out that its applications are being examined about 17,000 times daily from China and 50,000 times daily from South Korea.

The report claims that Chinese pirates and counterfeiters are now defending themselves with a new technique called “A Great Wall of Patents.” This process involves filing for patents in China for the products copied. The applications are claimed to use modified drawings and descriptions taken from the patent office Internet sites in the United States, Europe and Japan.

The report finds three patent crises for the United States: piracy costs U.S. IP owners about $50 billion a year; patent pendency rates are close to 30 months, which is impeding introduction of newer and better technologies; and the U.S. 18-month rule allows copying of proprietary U.S. technology.

The industry has often said that once IP violators become IP owners, both the respect for IP and its protection will increase. The good news for everyone involved is that IP ownership is indeed gaining ground in Asia, according to statistics from the World Intellectual Property Organization (WIPO). The WIPO, headquartered in Geneva, Switzerland, is a specialized agency of the United Nations. It administers the Patent Cooperation Treaty (PCT), which involves 128 countries, and 22 other international treaties dealing with IP protection.

March 20, 2006

Semiconductor International - Cognex Acts to Protect Customers from Abusive Patent Trolling; Lawsuit Against Acacia Research Corporation and Veritec Seeks Declaration of Invalidity, Unenforceability, and Non-Infringement of 2D Symbology Patent

Semiconductor International - Cognex Acts to Protect Customers from Abusive Patent Trolling; Lawsuit Against Acacia Research Corporation and Veritec Seeks Declaration of Invalidity, Unenforceability, and Non-Infringement of 2D Symbology Patent:


Cognex Corporation (NASDAQ: CGNX), the world's leading supplier of machine vision systems, announced today that it has served a complaint against Acacia Research Corporation and Veritec, Inc. The complaint was filed in the United States District Court in Minnesota.

Cognex is seeking a declaration that U.S. Patent 5,612,524, which claims to cover a system for reading 2D symbology, is invalid, unenforceable, and not infringed by either Cognex or by any users of Cognex products. The patent has not been asserted against Cognex, but, nevertheless, Cognex has taken this action to protect its customers who have received demand letters.

"Cognex firmly believes in the right of inventors and patent holders to seek licensing fees for legitimate, patented technology. But, we strongly object when questionable patents are used to extort payments from companies that do not have the expertise to challenge the patents, or who, for business reasons, decide to submit to licensing demands rather than to undertake costly legal challenges," said Dr. Robert J. Shillman, Cognex's Chairman and CEO.

CIRA Suspends Participation in ICANN

CIRA Suspends Participation in ICANN:


The Canadian Internet Registration Authority (CIRA) has issued a public letter to ICANN calling on the organization to follow accountable, transparent, and fair processes. Until the concerns are addressed, CIRA says it is suspending its voluntary contributions to ICANN... more...

March 17, 2006

Google, AOL still working out details of business deal

Google, AOL still working out details of business deal:


Blog: Google and America Online are still working out the details of their renewed business relationship. According to documents Google...

TradingMarkets.com - Daytrading, Eminis, Forex trading, Swing Trading

TradingMarkets.com - Daytrading, Eminis, Forex trading, Swing Trading:


(RTTNews) - Thursday, Oracle Corp. (ORCL | charts | news | Powerrating) said that it has won summary judgment in a significant patent infringement suit concerning its clustered database software. The ruling ends the proceedings against Oracle, but allows Oracle to proceed on its claims that MangoSoft's patent is invalid and unenforceable.

On March 14, 2006, the U.S. District Court in New Hampshire ruled in favor of Oracle on its motion for summary judgment that it did not infringe a patent held by MangoSoft, Inc. MangoSoft sued Oracle in 2002, claiming infringement of its patent on shared memory technology. It sought an injunction to stop Oracle from further sales of its software and over $500 Million in damages.

Oracle spokesperson Deborah Hellinger, said, "The case is an important victory for Oracle. This decision eliminates the threat to continued sales and revenues, and demonstrates the company's resolve to vigorously defend against unfounded claims attacking its products."

March 16, 2006

EarthLink invests $50 million in Covad | CNET News.com

EarthLink invests $50 million in Covad | CNET News.com:


EarthLink said Thursday that it has made a $50 million equity investment in Covad Communications Group to fund the expansion of the companies' co-developed voice services to eight new markets.

As part of the deal, EarthLink will receive $10 million in Covad common shares and $40 million in convertible debt, due in 2011.

Covad, a broadband access wholesaler, will use the money to fund infrastructure construction so that EarthLink can offer its line-powered voice service using the Covad network in Atlanta, Chicago, Los Angeles, Miami, New York, Philadelphia, San Diego and Washington, D.C.

Google wins a court battle | CNET News.com

Google wins a court battle | CNET News.com:


In a legal win for Google, a federal judge dismissed a lawsuit filed by a writer who claimed the search giant infringed on his copyright by archiving a Usenet posting of his and providing excerpts from his Web site in search results.

The lawsuit was filed by Gordon Roy Parker, also known as Ray Gordon, who publishes his writings under the business name of Snodgrass Publishing Group. Parker, of Philadelphia, also posted a chapter of one of his e-books on the Usenet bulletin board network, a collection of thousands of discussion forums called newsgroups.

In his 2004 lawsuit against Google, Parker alleged that the search giant violated copyright law by automatically archiving a copy of his posting on Usenet and by providing excerpts from his Web site in search results.

However, the U.S. District Court for the Eastern District of Pennsylvania ruled on Friday that under case law, Google's activities, akin to those of an Internet Service Provider, do not constitute infringement (click for PDF of court documents).

The Korea Times : Hynix Faces Patent Lawsuit in US

The Korea Times : Hynix Faces Patent Lawsuit in US:


Hynix Semiconductor faces the prospect of paying U.S. research firm Rambus up to $150 million in penalties for violating patent arrangements. The trial began in a U.S. court this week.

This is the third known legal battle facing the Korean semiconductor maker in the recent months, following the conviction of its executives for chip price-fixing in the U.S., and a formal complaint by Japan about alleged subsidization.

Hynix, the world’s second largest DRAM (dynamic random access memory) maker, is being sued by Rambus for infringing its patents of DRAM from 2000. After a six-years of legal saber rattling, the jury trial started on Monday with a verdict expected within a month. The verdict could order Hynix to pay royalties for its $4.4 billion sales in the United States since 2000.

Patent Baristas: FDA Outlines Critical Path Opportunities List

Patent Baristas: FDA Outlines Critical Path Opportunities List:


The Food and Drug Administration (FDA) released an initial list of priority research projects that could advance innovation in medical products. The announcement of the Critical Path Opportunities List signals the next major step in FDA's Critical Path Initiative aimed at modernizing medical product development, so new medical discoveries are brought to patients faster and at a lower cost.

Critical Path is the FDA's initiative to identify and prioritize the most pressing medical product development problems and the greatest opportunities for rapid improvement in public health benefits. Its primary purpose is to ensure that basic scientific discoveries translate more rapidly into new and better medical treatments by creating new tools to find answers about how the safety and effectiveness of new medical products can be demonstrated in faster timeframes with more certainty, at lower costs, and with better information.



Java Start-Up Sues Sun Over Software Patents @ SYS-CON AUSTRALIA

Java Start-Up Sues Sun Over Software Patents @ SYS-CON AUSTRALIA:


A dispute over Azul's alleged infringement of Sun's patents has taken a new twist, with the small Java firm claiming that it has been threatened. Azul Systems, a company selling hardware to run Java programs, has sued Sun Microsystems in a dispute about software patent fees and royalties. Azul filed for declaratory relief on 15 March, 2006, "to protect the interests of the company in the face of unfounded allegations from Sun Microsystems". Azul says the larger company threatened to sue if it didn't pay an "exorbitant" amount, giving Sun part ownership.

Azul wants a judge in the Northern California region's US District Court to declare a judgment against Sun that Azul doesn't infringe a list of 20 Sun patents or that those patents are invalid, according to a complaint filed by the company. Several of those patents involve processors running multiple tasks at once - a technology that both Sun and Azul are pursuing through development of multicore chips.

Sun’s reacted by stating, "Sun has spent over a year trying to achieve a business resolution to Azul's unauthorized use of Sun intellectual property. During this period, Azul has repeatedly stonewalled and delayed. The latest example of this behavior is the filing of the present action despite an agreement the parties entered into allowing additional time for business negotiations to take place, and despite the fact the parties were exploring additional avenues of resolving this dispute."


New 2ME2 Patent Strengthens EntreMed's Position in Cancer and Non-Oncology Diseases

New 2ME2 Patent Strengthens EntreMed's Position in Cancer and Non-Oncology Diseases:


ROCKVILLE, Md., March 16 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the issuance of U.S. Patent No. 7,012,070 covering methods of treatment for a broad range of indications with its lead clinical-stage compound, 2-methoxyestradiol (2ME2). Panzem(R) NCD, an oral formulation of 2ME2, is currently in Phase 2 clinical trials for cancer. Panzem(R) is also in preclinical development for rheumatoid arthritis. (Logo: Newscom: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

Patent No. 7,012,070, entitled "Estrogenic Compounds as Anti-Mitotic Agents," contains claims granted by the U.S. Patent Office covering 2ME2 for the treatment of multiple indications, including cancer and inflammatory disorders such as rheumatoid arthritis. The patent claims cover methods of treating a broad range of disease indications with 2ME2 that is independent of mechanism, including solid tumors or tumor metastases, immune and inflammatory diseases, including rheumatoid arthritis. The patent is owned by Children's Hospital Boston and licensed exclusively worldwide to EntreMed, Inc Panzem(R) (2ME2) is a novel anticancer agent, which is part of a next generation of antimitotic cancer drugs that bind to tubulin and work through multiple cellular pathways. 2ME2 can attack tumors on multiple fronts -- directly by disrupting microtubules, an intracellular matrix necessary for the rapid division of cancer cells (mitosis), by inducing programmed cell death (apoptosis), and by blocking blood vessels that feed tumors (angiogenesis inhibition).

This Blog Covered By A Creative Commons License Enforceable In The Netherlands

This Blog Covered By A Creative Commons License Enforceable In The Netherlands:


Creative_c.gif

This blog is published under a Creative Commons license that allows for non-commercial use. Adam Curry recently sued to enforce his CC license in Amsterdam and prevailed. This appears to be the first time a CC license has been evaluated in a court (if you're aware of others, please advise).

No comment from Prof. Lessig (discoverer of the CC license) yet.

Commentary from Prof. Patry with many links here.


March 15, 2006

BetaNews | Sun Partner Cries Foul in Patent Spat

BetaNews | Sun Partner Cries Foul in Patent Spat:


Mountain View, Calif.-based Java hardware company Azul filed for declaratory relief in order to "protect the interests of the company" from Sun Microsystems, the company said in a statement Wednesday.

Azul says Sun is attempting to force the company into paying an "exorbitant" sum of money to settle patent infringement allegations, as well as demanding part ownership of Azul and high up-front fees and royalties on the hardware the company sells.

If Azul does not comply, Sun has threatened with legal action, according to the allegations.

"Attempts to reach an agreement failed when Sun gave Azul an ultimatum: accept its final proposal or face litigation," Azul said in a statement. The company says the issues surround claims that it has misappropriated trade secrets and infringed on Sun's patents.

Could Holograms Be The Next Generation Of Trademarks?

Could Holograms Be The Next Generation Of Trademarks?:


Recently, many people in the intellectual property field have commented that all of the good or valuable trademarks have been exhausted, and all new trademark applications are previously (or currently) used marks filed on differing goods or services. Although these views on trademarks are probably not entirely true, less conventional options for trademarks are worth considering when developing a brand.


One untapped source for trademarks are holograms. Holograms are most notably used for anti-counterfeiting purposes. Businesses use them to distinguish their products from fakes. Take drivers’ licenses as an example. Most, if not all states, issue drivers’ licenses with state specific holograms to signify that the license is authentic.


Similarly, businesses should be able to use holograms as a source identifier and a means to distinguish goods or services from others in the marketplace. All of the existing trademark laws should still apply. Therefore, a useful hologram should be distinctive enough to be used to uniquely identify itself and its products or services to consumers.


In Holograms The next generation of trademarks? (appearing in the latested issue of IP Review), Dr. Ralf Sieckmann offers the following advice for registering a holographic device as a trademark:


-Describe the hologram in as much detail as possible, providing visual views of the hologram in various frames with descriptions of angle and appearance.


-File holograms in countries that have a liberal view on the registration of simple holograms, such as in France, Australia and the United States.


-If a country’s trademark procedures are too restrictive, consider filing an international application through one of these countries first. Once registered, WIPO will simply duplicate the trademark as an international trademark, and it will be up to each country to determine the registerability of the hologram mark.


-Last, but not least, if such an approach does not work, an alternative is to file a national or Community Design. Such designs can be registered on packaging, as a film or on other parts, provided the hologram is new or less than 12 months on the market.


When considering your next tradmark, think about using holograms. The are a vast number of options... at least for now, anyway.



Patent Issued to ProactiveNet Inc.

blackenterprise.com:


ProactiveNet Inc., the time-to-value leader in Business Services Management (BSM), today announced it has received its third U.S. Patent. This third patent (No. 6,816,898) extends the company's technology leadership position for IT service analytics and further strengthens the protection of ProactiveNet's intellectual property.

The patent describes a methodology that enables ProactiveNet to easily pull in performance data, in real-time, from any external source. The value in this technology is that ProactiveNet customers can easily add their own custom metrics, which are then leveraged by ProactiveNet's patented data correlation and analytics engine. In fact, ProactiveNet is the only BSM solution that can link customized data and key business metrics, such as online dollar sales per hour, with detailed performance data from the end-to-end IT infrastructure in real-time.


What Right in Digital Actors?

What Right in Digital Actors?:


A Copyfight reader pointed me to a Slate story on digital thespians. Epstein talks about two kinds of digital creations: wholly new 'synthespians' as well as digitized representations of actual actors (Tom Hanks for Polar Express; Sean Connery for the From Russia with Love game). Although the technical hurdles to such captures remain quite large - especially if your goal is true-to-life, fool-an-audience reproduction - the reader's question was different.

To wit: what rights do you purchase/license/contract for in creating such a reproduction of a real person? Rights to the "likeness?" Performance rights? Do either of these cover things the actor never physically did or said? Is there an exclusivity clause? There are clearly some issues around the ownership of a character, if that character has appeared before (e.g. Connery's Bond) but usually the character rights reside with the studio. But if you want the Connery Bond instead of a generic James Bond you also have to incude Connery in the deal, as well as whatever studio or estate has the Bond character rights.

IANAL, but I'm hoping some of my readers are or can point me to resources from people who've actually worked in this area.



March 14, 2006

BBC NEWS | Technology | Google set for court in data spat

BBC NEWS | Technology | Google set for court in data spat:


Google is to take on the US government in court on Tuesday as the internet search engine fights demands to hand over records and lists of data.
The Justice Department wants Google to provide a week's worth of search records, saying it needs the data to help it better police cyberspace.

But Google complains that complying with the request would compromise its business and the privacy of its users.

Similar requests were made of other net firms such as Microsoft, Yahoo and AOL.



Wipo Director Opens Conference

ag-ip-news.com (Intellectual Property News Agency)AGIPNEWS2816:


GENEVA - The World Intellectual Property Organization (WIPO) announced in a Tuesday press release that the Director General Dr. Kamil Idris, in the presence of Singapore’s Deputy Prime Minister, Professor S. Jayakumar, opened on March 13, 2006, a diplomatic conference on intellectual property (IP) for a new treaty in the field of trademarks.

It is the first time that a diplomatic conference organized by WIPO is held in Asia. On March 14, 2006, Dr. Idris attended the first plenary session, which resulted in the election of Singapore’s Permanent Representative to the United Nations in Geneva Ambassador Burhan Gafoor, as President of the Diplomatic Conference for the Adoption of a Revised Trademark Law Treaty (TLT).

UltraDNS Extends Leading Managed DNS Service Behind the Corporate Firewall

UltraDNS Extends Leading Managed DNS Service Behind the Corporate Firewall:


Managed internal DNS service provides a high performance, cost-effective solution to address the increased complexity of corporate IP networks. more...

Answers from Vint Cerf: The Road Ahead for Top-Level Domains

Answers from Vint Cerf: The Road Ahead for Top-Level Domains:


Earlier this year we requested your questions on one of ICANN's most heated discussions -- issues involving top-level domains (TLDs) -- which we passed on to Vint Cerft, Google's VP and Chief Internet Evangelist and chairman of the board of ICANN. Despite an understandably heavy schedule, Vint Cerf has taken the time to personally respond to more questions than we had originally anticipated. So with a special thanks, here are his responses. more...

March 13, 2006

Government Sides Against EBay in Patent Dispute

Government Sides Against EBay in Patent Dispute:


The federal government yesterday took a position against eBay Inc. in a patent dispute that threatens to shut down one of the online auction site's popular shopping features.

The Office of the Solicitor General said in a brief filed with the Supreme Court that eBay willfully infringed on patents held by Great Falls-based MercExchange LLC and should be enjoined from using its "Buy It Now" feature, which allows users to buy goods at fixed prices rather than compete in auctions. Goods sold using that system account for about a third of eBay's business.

GLASS ON WEB - Glass News - Court Ruling Upholds Corning Patent

GLASS ON WEB - Glass News - Court Ruling Upholds Corning Patent:


Corning Incorporated announced that the United States District Court for the District of Delaware has issued a ruling in its favor. The Court's ruling declared fully enforceable a patent exclusively licensed to Corning for optical biosensors that enable label-independent detection of chemical, biochemical and biological substances in a sample. The Court further concluded that Corning is entitled to a permanent injunction against SRU Biosystems of Woburn, MA, which infringed on the patent and induced a customer to infringe the patent through its testing activities.


Top Officials to Open Diplomatic Conference...

ag-ip-news.com (Intellectual Property News Agency)AGIPNEWS2807:


GENEVA - A major conference to revise a key international treaty in the field of trademarks, convened by the World Intellectual Property Organization (WIPO), opens on Monday in Singapore in the presence of top officials.

According to a press release by the Organization, the three-week conference will be formally launched by WIPO Director General, Dr. Kamil Idris, in the presence of Singapore’s Deputy Prime Minister and Minister for Law, Professor S. Jayakumar. High-ranking diplomatic delegations from the 183 WIPO member states, many led by senior officials, as well as observer delegations representing the branded goods industry and the trademark profession, will be attending the conference.

Seventh US Patent Issued to Analytical Spectral Devices, Inc. Related to Verification of Pharmaceuticals

Seventh US Patent Issued to Analytical Spectral Devices, Inc. Related to Verification of Pharmaceuticals:


Analytical Spectral Devices, Inc. (ASD), manufacturer of precision analytical instruments for real-time, field based material identification and verification, announced today that the United States Patent and Trademark Office has issued Patent Number 7,006,214 related to ASD’s innovative solution, RxSpec® technology.

Boulder, Colo., March 10, 2006 — Analytical Spectral Devices, Inc. (ASD), manufacturer of precision analytical instruments for real-time, field based material identification and verification, announced today that the United States Patent and Trademark Office has issued Patent Number 7,006,214 related to ASD’s innovative solution, RxSpec® technology.

“This is ASD’s seventh patent covering pharmaceutical verification and the second patent specifically related to our RxSpec® drug verification solution” says Dave Rzasa, President and CEO. “These patents further strengthen ASD’s leadership position in providing solutions to furthering pharmacist productivity, while at the same time combating counterfeits.”

ASD’s patented RxSpec® technology utilizes a combined visible and near infrared spectroscopy inspection system to directly check the prescription drug while in the dispensing vial. The real-time measurement is sensitive to chemical composition, color, and dosage level. The measured “chemical fingerprint” is compared to an extensive known database, thereby providing absolute assurance that the dispensed drug is correct in both type and concentration, regardless of similarity in appearance. In seconds, RxSpec® technology verifies the identity and dosage of a prescription drug dispensed by a pharmacy, thereby reducing potentially harmful filling errors, as well as detecting counterfeit drugs. And because RxSpec® technology is non-destructive, it can be used to inspect 100% of the prescriptions prepared by a pharmacy.

March 12, 2006

BlackBerry hits the acquisition path - Breaking - Technology - smh.com.au

BlackBerry hits the acquisition path - Breaking - Technology - smh.com.au:


The maker of BlackBerry email devices, fresh from settling a lawsuit that threatened its very business, is buying a company that will allow it to marry BlackBerries with corporate phone systems.

"It makes your BlackBerry perform just like your desktop phone," said Jim Balsillie, co-chief executive of the company behind the BlackBerry, Research in Motion Ltd.

RIM announced Friday that it has bought Ascendent Systems, a company that makes software for connecting mobile-phones to a corporate phone switch, or PBX.

Ascendent's software will be merged into RIM's later this year, enabling office-phone functions like simultaneous ringing at several locations, call transfer and spontaneous teleconferencing, Balsillie said.

The two companies have been partners, but Ascendent's software was sold separately. Balsillie said it will work with any type of PBX.

"So many of our customers were asking for the functionality of Ascendent, it really made it natural to start to integrate it into the core offering," Balsillie said.

WAVY.COM - Virginia company suing Missouri utility firm

WAVY.COM - Virginia company suing Missouri utility firm:


KANSAS CITY, Mo. A Virginia company has filed a federal patent infringement lawsuit against Kansas City Power and Light, in Missouri.

The lawsuit was filed in Kansas City by attorneys for Georgia Technologies, based in McLean, Virginia. It claims that K-C-P-and-L has been illegally using the other company's patented technology in the utility's electronic billing system.
The system allows K-C-P-and-L customers to view their statements and pay bills from their home computers.
The lawsuit asks a judge to order the utility to stop using the technology. It also seeks triple damages for the alleged infringement.

SEMA - "Stop Counterfeiting in Manufactured Goods Act"

SEMA - "Stop Counterfeiting in Manufactured Goods Act":


found 2006-03-12 17:10:23

Get the latest IP related decisions and office notices dated 12 March 2006

Get the latest IP related decisions and office notices dated 12 March 2006:


Latest news about intellectual property, patents, trademarks, ...

Building IP Portfolios Based On Competitive Intelligence

Building IP Portfolios Based On Competitive Intelligence:

One way to develop an intellectual property portfolio is to use up-to-date and accurate competitive intelligence on industry competitors as a map to lay out your company’s intellectual property procurement and enforcement strategies.

Competitive intelligence is an ongoing initiative to discover, analyze and use intelligence on competitors’ intellectual property, sales, marketing, regulatory filings and other publicly available information to become more competitive in the marketplace.

Compiling competitive intelligence is an ongoing process. Using modern technology as well as more traditional methods, it is less difficult than ever before to keep tabs on industry players.

The Internet is a key source to use to identify intellectual property (both published and issued patents for example), learn about marketing strategies on company websites, and look up publicly available information about products submitted for regulatory approval. There are also subscription services that deliver information. For example, services exist that tabulate marketing and sales data for specific industries. It is also possible to obtain information through common sources, i.e., vendors, manufacturers and distributors that work with multiple competitors. Lastly, it is possible to collect valuable information at industry trade shows and conferences.

Accounting, Tax and Reporting Treatments For Patents

Accounting, Tax and Reporting Treatments For Patents:


When determining the “value” of a patent, some businessmen and attorneys try to ascertain a theoretical numerical value that represents a patent’s “worth”. In other words, if they wanted to sell a particular patent, they are looking to calculate how much they could get for it. However, that isn’t the only patent value worth determining.


Another “value” of a patent is the “associated” value. This is a value accounts often refer to and record with respect to patents.


There are two common scenarios accounts use for financial and tax reporting treatments of patents. Depending on whether a patent was developed within an organization or whether it was purchased as an asset will determine which scenario is appropriate.


If a patent was developed within an organization or company:



1.Reflected As Asset On Financial Statements: Associated costs for developing the patent are deducted as current operating expenses. This is common for companies reporting on the cash basis of accounting or another consistent basis of accounting other than the GAAP (Generally Accepted Accounting Principles). When this cash basis situation occurs, the development cost of the patent is not reflected as an asset on the balance sheet of the company. However, the legal fees and filing costs associated with the patent are carried as an intangible asset on the financial statements of the company.


If legal costs are incurred to defend the patent rights, those costs are capitalized as an asset if the defense of the patent is successful. If defense of the patent is unsuccessful, legal costs of defense are expensed.

March 10, 2006

Microsoft faces new fines threat

Microsoft faces new fines threat:


Microsoft could soon face daily fines as its efforts to comply with a 2004 anti-trust ruling are "inadequate", Brussels warns.

March 04, 2006

Settlement ends Blackberry case

Settlement ends Blackberry case:


The maker of the Blackberry reaches a $612.5m deal to end a legal case that could have closed its US service.